Parmax Pharma share news, announcements and annual reports
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Parmax Pharma share news and announcements
390 announcements, routine notices left out, newest first. Page 2 of 8.
Feb 2026
10 Feb · Board meeting
Meeting on 14 Feb 2026: quarterly results
Nov 2025
10 Nov · Board meeting
Meeting on 14 Nov 2025: quarterly results
Oct 2025
Sep 2025
30 Sep · Meeting
6 Sep · Meeting
Aug 2025
14 Aug · Management
14 Aug · Financial Statements For Quarter Ended 30Th June 2025
14 Aug · Management
14 Aug · Results
14 Aug · Results
8 Aug · Board meeting
Meeting on 14 Aug 2025: quarterly results
Jul 2025
1 Jul · Management
May 2025
21 May · Board meeting
Meeting on 30 May 2025: audited results and quarterly results
Apr 2025
21 Apr · Compliance Certificate Under Regulation 7(3) Of SEBI (LODR), 2015 For The Year Ended On 31St March, 2025.
Feb 2025
6 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Dec 2024
2 Dec · Reason For Delay In Filing Financial Statements For The Quarter Ended On 30Th September, 2024.
Nov 2024
6 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Oct 2024
Sep 2024
Aug 2024
6 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results
Jun 2024
May 2024
31 May · Certificate For Non Applicability Of The Provision Of Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Year Ended On 31St March, 2024.
21 May · Board meeting
Meeting on 30 May 2024: audited results